Angela Meade

4.3k citations

50 papers · 2.1k indexed · h-index 17

Impact in

Oncology top 1%
- Colorectal Cancer Treatments and Studies
- Cancer Treatment and Pharmacology
- Colorectal Cancer Surgical Treatments
Hepatology top 2%
- Hepatocellular Carcinoma Treatment and Prognosis

Papers in

Oncology 36
- Colorectal Cancer Treatments and Studies 34
- Cancer Treatment and Pharmacology 14
Cancer Research 11
- Cancer Genomics and Diagnostics 11

Co-authors: Michel Seymour Tim Maughan Susan D. Richman Philip Quirke Catherine Daly Mahesh Parmar Faye Elliott Jennifer H. Barrett
Journals: Journal of Clinical Oncology (18 papers)Annals of Oncology (8 papers)European Journal of Cancer (3 papers)Clinical Cancer Research (2 papers)British Journal of Cancer (2 papers)
Partner nations: United Kingdom Australia United States

In The Last Decade

Angela Meade

48 papers receiving 2.0k citations

Peers

Countries citing papers authored by Angela Meade

Since Specialization

Citations

This map shows the geographic impact of Angela Meade's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Angela Meade with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Angela Meade more than expected).

Fields of papers citing papers by Angela Meade

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Angela Meade. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Angela Meade. The network helps show where Angela Meade may publish in the future.

Co-authors

The 25 scholars most cited alongside Angela Meade, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Angela Meade Line = papers co-authored together Angela Meade links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	Determining the Impact of Histology on the Incidence, Pattern, and Timing of Recurrences in Patients with Renal Cell Carcinoma: A Pooled Analysis from the SORCE and ASSURE Trials European Urology Open Science ·Bhavna Oza, Eleni Frangou, Tim Eisen, Grant D. Stewart, Axel Bex, David J. Harrison, Mahesh Parmar, Ruth E. Langley, Duncan C. Gilbert, Angela Meade	2025	0
2	LBA93 First results from RAMPART: An international phase III randomised-controlled trial of adjuvant durvalumab monotherapy or combined with tremelimumab for resected primary renal cell carcinoma (RCC) led by MRC CTU at UCL Annals of Oncology ·Stephen Grueniger, Nicolene Schuld, Eleni Frangou, Grant D. Stewart, Silas Kudakwashe Bere, Ian D. Davis, Martin R. Stockler, C. Suárez Rodríguez, B. Venugopal, Paul Nathan, Yicheng Huang, Craig Gedye, David J. Harrison, Tim Eisen, Ayelet Sheer, Hilary Plant, Hannah Rush, Babak Choodari‐Oskooei, Mahesh Parmar, Angela Meade	2025	0
3	Optimal maintenance strategy following FOLFOX plus anti-EGFR induction therapy in patients with RAS wild type metastatic colorectal cancer: An individual patient data pooled analysis of randomised clinical trials European Journal of Cancer ·Alessandra Raimondi, Federico Nichetti, Arndt Stahler, Harpreet Wasan, Enrique Aranda, Giovanni Randon, Annika Kurreck, Angela Meade, Eduardo Díaz‐Rubio, Monica Niger, Sebastian Stintzing, Federica Palermo, Zbigniew Rusinowski, Michele Prisciandaro, 森口佳映, David J. Fisher, Federica Morano, Filippo Pietrantonio, Dominik Paul Modest	2023	7
4	External Validation of the 2003 Leibovich Prognostic Score in Patients Randomly Assigned to SORCE, an International Phase III Trial of Adjuvant Sorafenib in Renal Cell Cancer. Apollo (University of Cambridge) ·Bhavna Oza, Tim Eisen, Eleni Frangou, Grant D. Stewart, Axel Bex, A.W.S. Ritchie, Richard Kaplan, J. P. Lipton, Ian D. Davis, Martin R. Stockler, Laurence Albigès, Bernard Escudier, James Larkin, Steven Joniau, Barry W. Hancock, Gregers G. Hermann, Joaquim Bellmunt, Mahesh Parmar, Patrick Royston, Angela Meade	2022	10
5	What Survival Benefits are Needed to Make Adjuvant Sorafenib Worthwhile After Resection of Intermediate- or High-Risk Renal Cell Carcinoma? Clinical Investigators’ Preferences in the SORCE Trial PubMed ·Nicola Jane Lawrence, Andrew Martin, Ian D. Davis, Sally Binks, Shomik Sengupta, Elizabeth Hovey, Xanthi Coskinas, Richard Kaplan, J. P. Lipton, A.W.S. Ritchie, Angela Meade, Tim Eisen, Prunella Blinman, Martin R. Stockler	2018	4
6	Patients’ preferences for adjuvant sorafenib after resection of renal cell carcinoma in the SORCE trial: what makes it worthwhile? Annals of Oncology ·Prunella Blinman, 聡篠崎, Andrew Martin, Sally Binks, Shomik Sengupta, Elizabeth Hovey, Xanthi Coskinas, Richard Kaplan, A.W.S. Ritchie, Angela Meade, Tim Eisen, Martin R. Stockler	2017	12
7	Predicted benefits of adjuvant sorafenib after nephrectomy for renal cell carcinoma (RCC) in SORCE: an international, placebo-controlled, randomised phase 3 trial Annals of Oncology ·Nicola Jane Lawrence, Amelia Rodríguez Martín, Ian D. Davis, Sally Binks, Shomik Sengupta, Elizabeth Hovey, Xanthi Coskinas, Raphael Kaplan, Sang-Ho Lee, Angela Meade, Pauline van Tol, Prunella Blinman, Martin R. Stockler	2017	1
8	External data required timely response by the Trial Steering-Data Monitoring Committee for the NALoxone InVEstigation (N-ALIVE) pilot trial Contemporary Clinical Trials Communications ·Sheila M. Bird, John Strang, Deborah Ashby, Tang Wei, Roy Robertson, Sarah Welch, Angela Meade, Mahesh Parmar	2017	4
9	Analyses of 7,635 Patients with Colorectal Cancer Using Independent Training and Validation Cohorts Show That rs9929218 in CDH1 Is a Prognostic Marker of Survival Clinical Cancer Research ·Christopher G. Smith, David J. Fisher, Rebecca Harris, Tim Maughan, Amanda I. Phipps, Susan D. Richman, Michel Seymour, Ian Tomlinson, Dan Rosmarin, David Kerr, Andrew T. Chan, Ulrike Peters, Polly A. Newcomb, Shelley Idziaszczyk, Hannah D. West, Angela Meade, Richard Kaplan, Jeremy P. Cheadle	2015	16
10	Intermittent chemotherapy plus either intermittent or continuous cetuximab for first-line treatment of patients with KRAS wild-type advanced colorectal cancer (COIN-B): a randomised phase 2 trial The Lancet Oncology ·Harpreet Wasan, Angela Meade, Richard Adams, Richard H. Wilson, Cheryl Pugh, David J. Fisher, Sukatiman Sukatiman, Ayman Madi, Bruce Sizer, C. Lowdell, Gary Middleton, Rachel Butler, Richard Kaplan, Tim Maughan	2014	83
11	Somatic Profiling of the Epidermal Growth Factor Receptor Pathway in Tumors from Patients with Advanced Colorectal Cancer Treated with Chemotherapy ± Cetuximab Clinical Cancer Research ·Christopher G. Smith, David J. Fisher, Bart Claes, Tim Maughan, Shelley Idziaszczyk, Gilian Peuteman, Rebecca Harris, Michelle D. James, Angela Meade, Bharat Jasani, Richard Adams, Sarah Kenny, Richard Kaplan, Diether Lambrechts, Jeremy P. Cheadle	2013	86
12	Oxaliplatin/capecitabine vs oxaliplatin/infusional 5-FU in advanced colorectal cancer: the MRC COIN trial British Journal of Cancer ·Ayman Madi, David J. Fisher, Richard H. Wilson, Richard Adams, Angela Meade, Sarah Kenny, Laura Nichols, Michel Seymour, Harpreet Wasan, Richard Kaplan, Tim Maughan	2012	33
13	Intermittent versus continuous oxaliplatin and fluoropyrimidine combination chemotherapy for first-line treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial The Lancet Oncology ·Richard Adams, Angela Meade, Michel Seymour, Richard H. Wilson, Ayman Madi, David J. Fisher, Sarah Kenny, Laurent Lizotte Lavallée, Elizabeth Hodgkinson, Sigit Sudarmadi, P. Rogers, Harpreet Wasan, Stephen Falk, Simon Gollins, Tamas Hickish, E.M. Bessell, David Propper, Megan Kennedy, Richard Kaplan, Tim Maughan	2011	177
14	Does anti-EGFR therapy improve outcome in advanced colorectal cancer? A systematic review and meta-analysis Cancer Treatment Reviews ·Claire L. Vale, Jayne F. Tierney, David J. Fisher, Richard Adams, Richard Kaplan, Tim Maughan, Mahesh Parmar, Angela Meade	2011	76
15	A NOVEL COLORECTAL CANCER SUSCEPTIBILITY SNP IN THE EIF3H PROMOTER INFLUENCES PATIENT SURVIVAL AND RESPONSE TO TREATMENT Annals of Oncology ·Jeremy P. Cheadle, 貝沼関志, David I. Fisher, Tim Maughan, Valentina Moskvina, Angela Meade, Hannah D. West, Richard Kaplan	2010	1
16	THE ADDITION OF CETUXIMAB TO OXALIPLATIN-FLUOROPYRIMIDINE CHEMOTHERAPY IN FIRST-LINE ADVANCED COLORECTAL CANCER IN THE MRC COIN TRIAL: IDENTIFICATION OF POTENTIALLY RESPONSIVE SUBSETS OF PATIENTS Annals of Oncology ·Jiamei Cao, Richard Adams, T Nordic, Michel Seymour, Robert Wilson, Angela Meade, David I. Fisher, Ayman Madi, Jeremy P. Cheadle, Raphael Kaplan	2010	3
17	High throughput somatic profiling of the Ras-Raf-MAP and PI3K-PTEN-Akt pathways in advanced colorectal cancer and correlations with response to cetuximab Annals of Oncology ·Christopher G. Smith, Bart Claes, David I. Fisher, Hussein Alqarni, Richard Kaplan, Angela Meade, Diether Lambrechts, Tim Maughan, Jeremy P. Cheadle	2010	1
18	THE IMPACT OF MILD RENAL IMPAIRMENT ON THE TOXICITY OF OXALIPLATIN AND FLUOROPYRIMIDINE REGIMENS: EXPERIENCE IN THE MRC COIN TRIAL Annals of Oncology ·Ayman Madi, A. Borangiu, Richard Adams, Michel Seymour, Angela Meade, J Cassidy, Meredith Eldridge, Sarah Kenny, Richard Kaplan, Jiamei Cao	2010	2
19	ADDITION OF CETUXIMAB TO OXALIPLATIN-BASED COMBINATION CHEMOTHERAPY (CT) IN PATIENTS WITH K-ras WILD-TYPE ADVANCED COLORECTAL CANCER (ACRC): EFFECTS ON OVERALL SURVIVAL. MRC COIN (CR10) TRIAL RESULTS Annals of Oncology ·Hussein Alqarni, Jiamei Cao, T Nordic, Michel Seymour, Robert Wilson, Angela Meade, David I. Fisher, Ayman Madi, Sarah Kenny, Harpreet Wasan, Pauline Rogers, Elizabeth Hodgkinson, Bharat Jasani, Jeremy P. Cheadle, Raphael Kaplan	2009	1
20	Evaluation of the site(s) of glycation in human proinsulin by ion-trap LCQ electrospray ionization mass spectrometry Regulatory Peptides ·Aine McKillop, Angela Meade, Peter R. Flatt, Finbarr O’Harte	2003	11

About Angela Meade

Angela Meade is a scholar working on Oncology, Cancer Research, Pathology and Forensic Medicine, Pulmonary and Respiratory Medicine and Hepatology, having authored 50 papers that have together received 2.1k indexed citations. Recurring topics across this work include Colorectal Cancer Treatments and Studies (34 papers), Cancer Treatment and Pharmacology (14 papers), Genetic factors in colorectal cancer (13 papers), Cancer Genomics and Diagnostics (11 papers), Renal cell carcinoma treatment (9 papers), Lung Cancer Treatments and Mutations (8 papers), Gastric Cancer Management and Outcomes (7 papers) and Renal and related cancers (6 papers). The work is most often cited by research in Oncology (1.7k citations), Hepatology (452 citations), Pathology and Forensic Medicine (639 citations), Pulmonary and Respiratory Medicine (650 citations) and Cancer Research (262 citations). Angela Meade has collaborated with scholars based in United Kingdom, Australia and United States. Frequent co-authors include Michel Seymour, Tim Maughan, Susan D. Richman, Philip Quirke, Catherine Daly, Mahesh Parmar, Faye Elliott, Jennifer H. Barrett, Richard Adams and Philip Chambers. Their work appears in journals such as Journal of Clinical Oncology, Annals of Oncology, European Journal of Cancer, Clinical Cancer Research and British Journal of Cancer.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact